Targeting USP10 to regulate the DNA damage response in NSCLC

靶向 USP10 调节 NSCLC 中的 DNA 损伤反应

基本信息

  • 批准号:
    10112548
  • 负责人:
  • 金额:
    $ 21.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-12-03 至 2022-11-30
  • 项目状态:
    已结题

项目摘要

ABSTRACT Combating platinum resistance remains a daunting challenge in the treatment of lung cancer. Activation of the cellular DNA damage response (DDR) is an important determinant of cell sensitivity to cisplatin and other chemotherapeutic drugs, which eliminate tumor cells through induction of DNA damage and checkpoint activation. We have recently found that histone deacetylase 6 (HDAC6) may promote degradation of a key DDR protein, checkpoint kinase 1 (Chk1). The G2 cell cycle checkpoint is activated upon DNA damage in a Chk1- dependent mechanism, and prolonged G2 arrest could lead to apoptosis. We have also found that a deubiquitinating enzyme (DUB), ubiquitin-specific peptidase 10 (USP10), could stabilize HDAC6. Our group is the first to discover HDAC6's ubiquitin E3 ligase activity, but targeting HDAC6's E3 ligase activity pharmacologically is not currently possible. Therefore, we propose targeting USP10 to decrease the protein level of HDAC6, which in turn induces persistently high levels of Chk1 to activate a prolonged G2 checkpoint arrest upon cisplatin treatment, leading to apoptosis. Because the role of USP10 in cancer is context-dependent, we searched the TCGA databases and found that a high level of USP10 is associated with shorter overall survival (OS) in a subset of NSCLC with TP53 mutations from a cohort of ~1,000 NSCLC patients, indicating that USP10 may serve as an oncogene in this subset. Consistently, our preliminary data have shown that depletion of USP10 in TP53 mutant NSCLC xenografts drastically inhibits xenografts' growth and sensitizes them to cisplatin, indicating an oncogenic role for USP10 in this subgroup of NSCLC. Reports from other groups as well as ours have shown that HDAC6 stabilizes oncogenic mutant p53 (mutp53) and confers cisplatin resistance in NSCLC. Based on our preliminary data and the literature, we hypothesize that the USP10-HDAC6 axis down-regulates DNA damage response protein Chk1 to compromise the cell cycle checkpoint, leading to cisplatin resistance. Thus, targeting this axis would activate the checkpoint and destabilize oncogenic mutp53, which ultimately increases responsiveness to cisplatin and prolongs overall survival in NSCLC patients with TP53 mutations. To test this central hypothesis, we will first explore the mechanism by which the USP10-HDAC6 axis confers cisplatin resistance; we will then test the therapeutic potential of USP10 inhibition in treating TP53 mutant NSCLC and evaluate a correlation between USP10 expression and cisplatin response, as well as a correlation between expression of USP10's substrates and cisplatin response in a cohort of TP53 mutant NSCLC samples. The outcome of our proposal will establish the oncogenic role of USP10 in the mutp53 subset of NSCLC and provide a strong rationale for the development of clinically relevant USP10 inhibitors to treat this subset of NSCLC patients, thus improving cisplatin responses and overall survival.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GEROLD BEPLER其他文献

GEROLD BEPLER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GEROLD BEPLER', 18)}}的其他基金

Developmental Research Program
发展研究计划
  • 批准号:
    10289607
  • 财政年份:
    2021
  • 资助金额:
    $ 21.6万
  • 项目类别:
ETCTN Early Drug Development Opportunity Leadership program administrative supplement to Cancer Center Support Grant
ETCTN 早期药物开发机会领导计划对癌症中心支持补助金的行政补充
  • 批准号:
    10363981
  • 财政年份:
    2021
  • 资助金额:
    $ 21.6万
  • 项目类别:
Reducing Cancer Health Disparities in Detroit
减少底特律的癌症健康差异
  • 批准号:
    10289601
  • 财政年份:
    2021
  • 资助金额:
    $ 21.6万
  • 项目类别:
Developmental Research Program
发展研究计划
  • 批准号:
    10684289
  • 财政年份:
    2021
  • 资助金额:
    $ 21.6万
  • 项目类别:
Developmental Research Program
发展研究计划
  • 批准号:
    10491131
  • 财政年份:
    2021
  • 资助金额:
    $ 21.6万
  • 项目类别:
Targeting USP10 to regulate the DNA damage response in NSCLC
靶向 USP10 调节 NSCLC 中的 DNA 损伤反应
  • 批准号:
    10311543
  • 财政年份:
    2020
  • 资助金额:
    $ 21.6万
  • 项目类别:
Detroit Research on Cancer Survivors (Detroit ROCS)
底特律癌症幸存者研究(底特律 ROCS)
  • 批准号:
    10082435
  • 财政年份:
    2017
  • 资助金额:
    $ 21.6万
  • 项目类别:
Senior Leadership
高层领导
  • 批准号:
    8709336
  • 财政年份:
    2013
  • 资助金额:
    $ 21.6万
  • 项目类别:
Protocol Specific Research Support
协议特定研究支持
  • 批准号:
    8723966
  • 财政年份:
    2013
  • 资助金额:
    $ 21.6万
  • 项目类别:
Protocol Specific Research Support
协议特定研究支持
  • 批准号:
    8350790
  • 财政年份:
    2011
  • 资助金额:
    $ 21.6万
  • 项目类别:

相似海外基金

MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers
吸烟者和电子烟使用者急性电子烟暴露的 MRI 和生物标志物
  • 批准号:
    10490338
  • 财政年份:
    2021
  • 资助金额:
    $ 21.6万
  • 项目类别:
MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers
吸烟者和电子烟使用者急性电子烟暴露的 MRI 和生物标志物
  • 批准号:
    10353104
  • 财政年份:
    2021
  • 资助金额:
    $ 21.6万
  • 项目类别:
Investigating pollution dynamics of swimming pool waters by means of chemical and biological markers
利用化学和生物标记物研究游泳池水体的污染动态
  • 批准号:
    21K04320
  • 财政年份:
    2021
  • 资助金额:
    $ 21.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers
吸烟者和电子烟使用者急性电子烟暴露的 MRI 和生物标志物
  • 批准号:
    10688286
  • 财政年份:
    2021
  • 资助金额:
    $ 21.6万
  • 项目类别:
Novel biological markers for immunotherapy and comprehensive genetic analysis in thymic carcinoma
用于胸腺癌免疫治疗和综合遗传分析的新型生物标志物
  • 批准号:
    20K17755
  • 财政年份:
    2020
  • 资助金额:
    $ 21.6万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
  • 批准号:
    10578649
  • 财政年份:
    2019
  • 资助金额:
    $ 21.6万
  • 项目类别:
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
  • 批准号:
    10295141
  • 财政年份:
    2019
  • 资助金额:
    $ 21.6万
  • 项目类别:
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
  • 批准号:
    10041708
  • 财政年份:
    2019
  • 资助金额:
    $ 21.6万
  • 项目类别:
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
  • 批准号:
    9776149
  • 财政年份:
    2019
  • 资助金额:
    $ 21.6万
  • 项目类别:
Combining biological and non-biological markers to develop a model predictive of treatment response for individuals with depression
结合生物和非生物标志物来开发预测抑郁症患者治疗反应的模型
  • 批准号:
    2063934
  • 财政年份:
    2018
  • 资助金额:
    $ 21.6万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了